# Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets

> **NCT05637541** · PHASE2 · COMPLETED · sponsor: **Fujian Akeylink Biotechnology Co., Ltd.** · enrollment: 90 (actual)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** GST-HG141

## Key facts

- **NCT ID:** NCT05637541
- **Lead sponsor:** Fujian Akeylink Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-03
- **Primary completion:** 2024-07-24
- **Final completion:** 2024-08-24
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05637541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05637541, "Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05637541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*